JP2022534069A5 - - Google Patents
Info
- Publication number
- JP2022534069A5 JP2022534069A5 JP2021569555A JP2021569555A JP2022534069A5 JP 2022534069 A5 JP2022534069 A5 JP 2022534069A5 JP 2021569555 A JP2021569555 A JP 2021569555A JP 2021569555 A JP2021569555 A JP 2021569555A JP 2022534069 A5 JP2022534069 A5 JP 2022534069A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- nucleotide sequence
- sequence
- sirna
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910441597.6 | 2019-05-24 | ||
| CN201910441597 | 2019-05-24 | ||
| PCT/CN2020/091606 WO2020238758A1 (zh) | 2019-05-24 | 2020-05-21 | 核酸、药物组合物与缀合物及制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534069A JP2022534069A (ja) | 2022-07-27 |
| JP2022534069A5 true JP2022534069A5 (enExample) | 2023-05-29 |
| JP7614650B2 JP7614650B2 (ja) | 2025-01-16 |
Family
ID=73553862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569555A Active JP7614650B2 (ja) | 2019-05-24 | 2020-05-21 | 核酸、薬物組成物及び複合体並びに調製方法と使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220315929A1 (enExample) |
| EP (1) | EP3992290A4 (enExample) |
| JP (1) | JP7614650B2 (enExample) |
| CN (1) | CN113891939B (enExample) |
| WO (1) | WO2020238758A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) * | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| EP4273245A4 (en) * | 2020-12-29 | 2024-12-11 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND SIRNA CONJUGATE WITH THE NUCLEIC ACID, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| AU2022357561A1 (en) * | 2021-10-01 | 2024-04-18 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
| TW202346586A (zh) * | 2022-01-28 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法 |
| CN120209051A (zh) * | 2023-12-27 | 2025-06-27 | 武汉人福创新药物研发中心有限公司 | 用于递送的靶向化合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| ES2702428T3 (es) | 2010-11-15 | 2019-02-28 | Life Technologies Corp | Reactivos de transfección que contienen amina y métodos para prepararlos y usarlos |
| KR102011156B1 (ko) * | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| EP4253395A3 (en) | 2012-08-06 | 2023-11-29 | Alnylam Pharmaceuticals, Inc. | Processes for the preparation of carbohydrate conjugated rna agents |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| US9670492B2 (en) * | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
| ES3065185T3 (en) * | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| HUE052709T2 (hu) * | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| CA2984636A1 (en) | 2015-05-06 | 2016-11-10 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
-
2020
- 2020-05-21 CN CN202080037247.4A patent/CN113891939B/zh active Active
- 2020-05-21 JP JP2021569555A patent/JP7614650B2/ja active Active
- 2020-05-21 US US17/595,576 patent/US20220315929A1/en not_active Abandoned
- 2020-05-21 EP EP20815633.1A patent/EP3992290A4/en not_active Withdrawn
- 2020-05-21 WO PCT/CN2020/091606 patent/WO2020238758A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533722A5 (enExample) | ||
| JP2022534702A5 (enExample) | ||
| JP2022533841A5 (enExample) | ||
| JP2021503941A5 (enExample) | ||
| JP2021503940A5 (enExample) | ||
| JP2022533421A5 (enExample) | ||
| JP2022535708A5 (enExample) | ||
| JP2022533419A5 (enExample) | ||
| JP2021503929A5 (enExample) | ||
| JP2021533800A5 (enExample) | ||
| JP2021503930A5 (enExample) | ||
| JP2022501059A5 (enExample) | ||
| JP2022535911A5 (enExample) | ||
| JP2022106928A (ja) | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 | |
| JP2023536320A5 (enExample) | ||
| JP2022017481A (ja) | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド | |
| HRP20250277T1 (hr) | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba | |
| JP2022528840A5 (enExample) | ||
| CA2879066C (en) | Chiral nucleic acid adjuvant | |
| JP2025165976A5 (enExample) | ||
| JP7748500B2 (ja) | トリループを含む二本鎖核酸インヒビター分子 | |
| HRP20250192T1 (hr) | Nukleinska kiselina, sastav i konjugat koji je sadrži, te metoda pripreme i uporaba | |
| CN113795582A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| JP2010538677A5 (enExample) | ||
| JP6757373B2 (ja) | キラルデザイン |